vTv Therapeutics Schedules Fireside Chat on Phase 3 Cadisegliatin at ROTH Conference
vTv Therapeutics announced management will present at the 38th Annual ROTH Conference on March 23 with a fireside chat and one-on-one investor meetings, including a live webcast. The company’s Phase 3 cadisegliatin oral therapy for type 1 diabetes, granted FDA Breakthrough Therapy designation, will likely be a key discussion topic.
1. Conference Participation Details
vTv Therapeutics will participate in the 38th Annual ROTH Conference from March 22 to 24, with management hosting a fireside chat and conducting one-on-one investor meetings on March 23 at 10:00 AM PDT. A live webcast of the presentation will be accessible via the company’s website, with on-demand replay available after the event.
2. Cadisegliatin Pipeline Highlight
The company’s lead asset, cadisegliatin (TTP399), is a novel oral glucokinase activator in a US Phase 3 trial for type 1 diabetes and has earned FDA Breakthrough Therapy designation. This potential first-in-class adjunctive therapy to insulin targets liver-selective glucokinase activation to improve glycemic control through enhanced hepatic glucose uptake and glycogen storage.